OZ-001 / Oncozen - LARVOL DELTA

A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer (Phase 1a) (ANZCTR) - P1 | N=18 | Recruiting | Sponsor: Oncozen Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Anti-proliferative effects of novel T-type calcium channel blocker KCP10043F in human pancreatic cancer cells through Ca2+/CaMKII pathway via ER stress induction. (PubMed, Life Sci) - "Although a T-type calcium channel blocker, 4-(4-fluorobenzylcarbamoylmethyl)-3-(4-cyclohexylphenyl)-2-[3-(N,N-dimethylureido)-N'-methylpropylamino]-3,4-dihydroquinazoline (KCP10043F, OZ-001), previously exhibited the anti-tumor effects in lung cancer, its anti-proliferative effects and the specific molecular mechanisms in pancreatic cancer remain unclear...1) KCP10043F suppressed cell growth and colony formation, and promoted the G1 phase cell retention by downregulating G1 phase-related proteins; 2) KCP10043F triggered apoptotic cell death via the intrinsic pathway by upregulating BH3-only Bcl-2 family proteins; 3) At the molecular level, KCP10043F inhibited the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (p70S6K) pathway and activated the c-Jun N-terminal kinase (JNK)/c-Jun pathway; 4) KCP10043F mediated the Ca2+/Calcium-calmodulin-dependent kinase II (CaMKII) pathway by inducing endoplasmic reticulum (ER) stress; 5)..."

Journal • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • AMPK • BCL2 • MAPK8

OZ-001 Suppresses the Growth of Triple-Negative Breast Cancer and Pancreatic Cancer by Targeting STAT3 Phosphorylation and the Calcium Signaling Pathway. (PubMed, Biomol Ther (Seoul)) - "In vivo, oral administration of OZ-001 significantly reduced tumor growth in both xenograft models, likely due to diminished STAT3 phosphorylation and associated tumorigenic processes. These findings demonstrate the potential of OZ-001 to serve as an effective therapeutic agent for treating TNBC and PDAC."

IO biomarker • Journal • Breast Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer • BCL2 • BIRC5 • CCND1

A Phase 1, Open-label. First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer (Phase 1b) (ANZCTR) - P1 | N=5 | Not yet recruiting | Sponsor: Oncozen Co.. Ltd

New P1 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer